Posts

The trial involved administering two different types of a shot that uses a cold-causing virus to deliver genetic code of HIV, spread over four vaccination visits in a year. J&J used a similar technology for its COVID-19 vaccine.

Raynham, Massachusetts-based DePuy Synthes first sued in 2018. Its amended 2021 complaint accused VOI of selling plates and screws used in knee surgery for dogs and other animals that infringed its patents.

Bayer predicted on Tuesday its experimental drug against dangerous blood clots could make more than 5 billion euros ($5.4 billion) in peak annual sales, as the company seeks to revive a share price that has drawn interest from activist investors.

On Thursday, Fate Therapeutics announced it terminated a 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen. In response, the next-generation cell therapy company’s stock sank by 54% in pre-market trading Friday. 

And then there were two. Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. 

Johnson & Johnson said on Tuesday it struck a deal to buy heart pump maker Abiomed Inc. for $16.6 billion in cash, as it looks to boost growth at its medical devices unit after next year’s planned spinoff of its consumer health business.

Eli Lilly and Co. on Tuesday forecast its annual profit and revenue below estimates, as a stronger dollar piled more pressure on the drugmaker struggling with lower insulin prices and generic competition for its cancer drug.

The therapy Tecvayli is a bispecific antibody, which is engineered to redirect body’s immune system to recognize and kill cancer cells. It is the first drug of its class to be approved for multiple myeloma.

Johnson & Johnson on Tuesday posted better than expected third-quarter earnings on strong demand for its cancer drug Darzalex, but said it may still cut some jobs as it contends with inflationary pressure and challenges created by the strong dollar.

The top pharma companies in 2021 continued to be engaged in creating vaccines and therapeutics, and the investments in R&D led to greater revenue and earnings.